Amarantus and BSI Announce Dr. Thomas Arendt as Presenter at 3rd Alzheimer's Focused #C4CT Concussion Awareness Summit at United Nations
NEW YORK and SAN FRANCISCO, July 23, 2014 (GLOBE NEWSWIRE) -- Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced a presentation by Dr. Thomas Arendt, Professor at University of Leipzig, at the 3rd Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY. Dr. Arendt will summarize his scientific hypotheses regarding the evolutional context of Alzheimer's disease, and an emerging therapeutic target in a 30 minute presentation in the afternoon session.
"I am pleased to accept the organizers' offer to present at #C4CT," said Dr. Arendt. "After being the first to identify the scientific principles underpinning Amarantus' diagnostic blood test LymPro, I have continued my research into Alzheimer's disease with a strong focus on human tissue evaluation from Alzheimer's patients. I believe there is a need to take a much broader perspective in thinking about Alzheimer's, and I am pleased to have this unique forum to share my perspective with the world."
Dr. Thomas Arendt is Professor of Neuroscience and runs the Paul Flechsig Institute of Brain Research which is a Research Institute of Leipzig University with about 50 staff members. He is also the Director of the Alzheimer Centre Leipzig and Director of the Interdisciplinary Centre for Clinical Research Leipzig. He has over 30 years of experience in R&D of therapeutic and diagnostic strategies of neurodegenerative disorders and has made several seminal contributions to therapeutic concepts of Alzheimer´s disease, including stem cell therapy and modulating tumor suppressor genes. He has published work in top-ranked journals, including Cell, Nature, J.Cell Biol., J. Neurosci., and holds several patents for CNS diagnostics and treatment with some of them out-licensed to biotech companies in the United States. Over the last 30 years, his research has continuously been funded by the German Research Foundation, German Federal Ministry for Education and Research, European Commission and others. In the early eighties of the 20th century, he was involved in identifying the degeneration of the cholinergic system in Alzheimer´s disease laying the basis for todays´ only available treatments. He is one of the pioneers of the "cell-cycle theory" of Alzheimer´s disease which he developed further towards a diagnostic and therapeutic concept.
The #C4CT Concussion Awareness Summit is being convened on July 31, 2014 to explore the potential link between TBI and Alzheimer's disease. A diverse working group of clinicians, medical researchers, policy makers, international diplomats, athletes, celebrities, and philanthropic organizations will be assembled to raise awareness, advance clinical research, and develop public policy in order to address this major unmet medical need and public health issue.
To register or for additional information, please visit www.c4ctsummit.com. For further event questions, please contact Lindsay Lommel at email@example.com. For sponsorship information please visit: http://www.c4ctsummit.com/sponsorship-opportunities/.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
About Brewer Sports International
Brewer Sports International (BSI) is a multi-faceted sports advisory firm within The Brewer Group Companies with a focus on the business of sports, wellness and media for professional athletes, sports agencies, public and private corporations and various partners including international organizations, governments and NGOs. Jack Brewer, five-year National Football League (NFL) veteran and former three-team captain, launched BSI in Minneapolis and expanded to New York, Dallas, Miami, Beijing and Malawi. BSI offers a unique financial services platform to professional athletes and sports agencies, as well as high-net-worth individuals and businesses related to professional sports. BSI takes pride in enabling its clients to capitalize on the endless opportunities presented through sport. For more information, please visit www.brewersports.com or follow them on Facebook, Twitter and LinkedIn.
About MDM Worldwide
MDM Worldwide Solutions, Inc. is a digital communications agency that develops and manages online engagement strategies to connect companies with their stakeholders. MDM specializes in working with clients in the technology, healthcare and life sciences spaces. MDM's vast industry knowledge, proprietary methodology, proven track record and experienced leadership team enables them to create and customize targeted digital marketing campaigns to fulfill all of their clients' objectives. For more information, please visit mdmworldwide.com or find them on Facebook, Twitter, Google+ and LinkedIn.
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
CONTACT: Brewer Sports International: Kristi Hofacker, Director of Interactive Marketing and Media 651.247.4460 firstname.lastname@example.org Amarantus Bioscience Holdings, Inc.: Aimee Boutcher, Investor Relations 408.737.2734 x 101 email@example.com